That’s a wrap on #ASTRO22! The last issue of the Daily News for ASTRO 2022 features a special message from ASTRO President Jeff Michalski, MD, MBA, FASTRO, coverage on Wednesday's Cancer Breakthroughs session, abstract commentary and CME reminders.
In one of the conference’s last but most highly anticipated sessions, Everett Vokes, MD, ASCO and Martha Matuszak, PhD from AAPM presented important findings from the ASCO and AAPM annual meetings.
SBRT for HCC
Phase II results comparing DEB-TACE to SBRT on patients with one to three HCC lesions with Childs-Pugh Class A liver disease.
Ablative RT for LAPC
Retrospective analysis of consecutive LAPC patients treated with either 50 Gy in 5 fractions using a 0.35T MR Linac and online adaptive replanning or 67.5-75 Gy in 15-25 fractions using CBCT guidance and selective offline adaptive replanning.
Radiation for ICI in HCC
Shu Jung Hsu, MD et al. presented their large retrospective study comparing immune checkpoint inhibitors (ICI) alone versus immune checkpoint inhibitors combined with radiation therapy (ICI-RT).
Bhavana Rai, MD, et al. presented their work on the use of circulating cell free DNA (cfDNA) as a minimally invasive and cost-effective potential biomarker that can be used for monitoring disease response.
HF Pelvic RT
Ajeet Gandhi, MD, DNB, presented their work on hypofractionated pelvic radiation in intact cervical cancer.
SBRT for VT
Ian J. Gerard, MD, CM, PhD, and colleagues have embarked on ambitious studies of providing patients with refractory ventricular tachycardia (VT) an additional treatment option: SBRT.